MedTrace Logo

MARC-2: MARKERS AND RESPONSE TO CRT in Non-LBBB

NCT04120909 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2019-10-09

No results posted yet for this study

Summary

The purpose of the MARC-2 study is to investigate the relation of the QRS area, determined by vectorcardiography, and response to Cardiac Resynchronization Therapy (CRT) in patients with a wide QRS complex and without a typical left bundle branch block; the interrelationship as well as the potential predictive power of this biomarker, as well as other clinical biomarkers on a hierarchal composite endpoint (death, heart failure hospitalizations, heart failure complaints and cardiac function) will be evaluated.

The main biomarker that is studied is the QRS area, but also other electrocardiographic, echocardiographic markers, blood markers and clinical markers will be studied.

Conditions

  • Cardiac Resynchronization Therapy, Non-LBBB, QRS Area

Interventions

DEVICE

Cardiac resynchronization therapy

Biventricular pacing according to current standards.

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Maastricht University Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04120909 on ClinicalTrials.gov